Incremento de supervivencia en melanoma - page 9

6.8m

22.8m

Pembrolizumab post-Ipi in melanoma:

Keynote 002

ORR 22-28% vs 4.5%

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6,7,8 10,11,12,13,14,15,16,17,18,19,...29